CD19 and cancer: Off-the-shelf NK cell cancer immunotherapy is also being actively explored by Fate Therapeutics, where allogeneic NK cells are derived from a clonal master iPSC line and further engineered with high-affinity CD16, IL-15 receptor fusion, or CAR (CD19, BCMA, B7H3, MICA/B).